brl 42810 has been researched along with Chickenpox in 10 studies
Chickenpox: A highly contagious infectious disease caused by the varicella-zoster virus (HERPESVIRUS 3, HUMAN). It usually affects children, is spread by direct contact or respiratory route via droplet nuclei, and is characterized by the appearance on the skin and mucous membranes of successive crops of typical pruritic vesicular lesions that are easily broken and become scabbed. Chickenpox is relatively benign in children, but may be complicated by pneumonia and encephalitis in adults. (From Dorland, 27th ed)
Excerpt | Relevance | Reference |
---|---|---|
"Two multicenter, open-label, single-arm, two-phase studies evaluated single-dose pharmacokinetics and single- and multiple-dose safety of a pediatric oral famciclovir formulation (prodrug of penciclovir) in children aged 1 to 12 years with suspicion or evidence of herpes simplex virus (HSV) or varicella-zoster virus (VZV) infection." | 5.14 | Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. ( Abrams, B; Arguedas, A; Bomgaars, L; De León Castrejón, T; Hamed, K; Kaiser, G; Looby, M; Roberts, M; Rodriguez, A; Sáez-Llorens, X; Spigarelli, MG; Yogev, R; Zhou, W, 2009) |
"Reactivation of varicella zoster virus (VZV) is a common event in patients undergoing allogeneic bone marrow transplantation (BMT) and may lead to life-threatening complications." | 2.69 | Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. ( Akhtar, M; DesJardin, J; Griffith, J; Koc, Y; Miller, KB; Schenkein, DP; Snydman, DR, 2000) |
"We examined the incidence of herpes varicella-zoster virus (VZV) infection in 151 patients undergoing allogeneic BMT between August 1990 and September 1997 and who survived at least 3 months." | 2.69 | Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. ( Beresford, JA; Grigg, A; Matthews, JP; Sasadeusz, J; Steer, CB; Szer, J, 2000) |
" Famciclovir and valacyclovir demonstrate superior pharmacokinetics compared with acyclovir and allow for less frequent daily dosing with higher achievable serum drug concentrations." | 2.40 | Management of herpes simplex and varicella-zoster virus infections. ( Erlich, KS, 1997) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (50.00) | 18.2507 |
2000's | 5 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sáez-Llorens, X | 1 |
Yogev, R | 1 |
Arguedas, A | 1 |
Rodriguez, A | 1 |
Spigarelli, MG | 1 |
De León Castrejón, T | 1 |
Bomgaars, L | 1 |
Roberts, M | 1 |
Abrams, B | 1 |
Zhou, W | 1 |
Looby, M | 1 |
Kaiser, G | 1 |
Hamed, K | 1 |
Brown, TJ | 1 |
McCrary, M | 1 |
Tyring, SK | 1 |
Ioannidis, J | 1 |
Wilkinson, D | 1 |
Easterbrook, P | 1 |
Wood, MJ | 1 |
Erlich, KS | 1 |
Wutzler, P | 1 |
Whitley, RJ | 1 |
Zeller, V | 1 |
Caumes, E | 1 |
Bricaire, F | 1 |
Koc, Y | 1 |
Miller, KB | 1 |
Schenkein, DP | 1 |
Griffith, J | 1 |
Akhtar, M | 1 |
DesJardin, J | 1 |
Snydman, DR | 1 |
Steer, CB | 1 |
Szer, J | 1 |
Sasadeusz, J | 1 |
Matthews, JP | 1 |
Beresford, JA | 1 |
Grigg, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Pharmacokinetics and Safety of Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection[NCT00098046] | Phase 3 | 76 participants (Anticipated) | Interventional | 2005-07-31 | Completed | ||
A Multicenter, Open-label, Single-arm, Two-step Study to Evaluate the Safety and Single-dose Pharmacokinetics of Famciclovir and Multiple-dose Safety After Administration of Famciclovir Oral Pediatric Formulation to Children 1 to 12 Years of Age With Herp[NCT00098059] | Phase 3 | 74 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
PK parameter; penciclovir is the active metabolite of famciclovir. (NCT00098059)
Timeframe: Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose
Intervention | L/h (Mean) |
---|---|
1 to < 2 Years | 20.8 |
2 to <6 Years | 25.1 |
6 to <=12 Years | 43.7 |
13 to <= 18 Years | 68.8 |
PK parameter; penciclovir is the active metabolite of famciclovir (NCT00098059)
Timeframe: Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose
Intervention | hours (Mean) |
---|---|
1 to < 2 Years | 1.09 |
2 to <6 Years | 1.36 |
6 to <=12 Years | 1.60 |
13 to <= 18 Years | 1.86 |
PK parameter; penciclovir is the active metabolite of famciclovir. (NCT00098059)
Timeframe: Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose
Intervention | (μg/mL)h (Mean) |
---|---|
1 to < 2 Years | 6.17 |
2 to <6 Years | 6.85 |
6 to <=12 Years | 8.15 |
13 to <= 18 Years | 5.93 |
PK parameter; penciclovir is the active metabolite of famciclovir. (NCT00098059)
Timeframe: plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose
Intervention | μg/mL (Mean) |
---|---|
1 to < 2 Years | 2.84 |
2 to <6 Years | 2.44 |
6 to <=12 Years | 2.82 |
13 to <= 18 Years | 1.89 |
PK parameter; penciclovir is the active metabolite of famciclovir. (NCT00098059)
Timeframe: Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose
Intervention | hours (Median) |
---|---|
1 to < 2 Years | 1.21 |
2 to <6 Years | 1.07 |
6 to <=12 Years | 1.00 |
13 to < =18 Years | 1.47 |
Overall acceptability of the study medication was determined by caretaker response. (NCT00098059)
Timeframe: Day 1, after swallowing the dose.
Intervention | participants (Number) | ||
---|---|---|---|
Badly | Neither bad nor good | Well | |
1 to < 2 Years | 1 | 1 | 2 |
13 to <=18 Years | 2 | 0 | 0 |
2 to <6 Years | 4 | 1 | 8 |
6 to <13 Years | 0 | 4 | 4 |
Overall acceptability of study medication was determined by caretaker response. (NCT00098059)
Timeframe: Day 8 at home: after swallowing last dose
Intervention | participants (Number) | ||
---|---|---|---|
Badly | Neither bad nor good | Well | |
1 to < 2 Years | 7 | 3 | 3 |
2 to <6 Years | 5 | 3 | 7 |
6 to <13 Years | 3 | 3 | 11 |
Overall acceptability of the study medication was determined by caretaker response. (NCT00098059)
Timeframe: Day 1 at clinic: after swallowing first dose
Intervention | participants (Number) | ||
---|---|---|---|
Badly | Neither bad nor good | Well | |
1 to < 2 Years | 9 | 2 | 2 |
2 to <6 Years | 6 | 1 | 9 |
6 to <13 Years | 7 | 2 | 9 |
A patient with multiple adverse events (AEs) within the primary system organ class is counted only once in total row. (NCT00098059)
Timeframe: 8 hours and 24 hours after study drug administration (Part A)
Intervention | participants (Number) | |||||
---|---|---|---|---|---|---|
Patients with AEs | Gastrointestinal disorders | Nervous system disorders | General disorders and administration site | Infections and infestations | Skin and subcutaneous tissue disorders | |
1 to < 2 Years | 0 | 0 | 0 | 0 | 0 | 0 |
13 to <= 18 Years | 2 | 1 | 1 | 1 | 0 | 0 |
2 to <6 Years | 2 | 1 | 0 | 0 | 1 | 1 |
6 to <=12 Years | 1 | 0 | 1 | 0 | 0 | 0 |
A patient with multiple AEs within the primary system organ class is counted only once in total row. (NCT00098059)
Timeframe: Administered 2 times daily over 7 days
Intervention | participants (Number) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Patients with AEs | Gastrointestinal disorders | Nervous system disorders | General disorders and administration site | Respiratory, thoracic and mediastinal disorders | Infections and infestations | Skin and subcutaneous tissue disorders | Vascular disorders | Injury, poisoning and procedural complications | Investigations | Metabolism and nutrition disorders | |
1 to < 2 Years | 6 | 4 | 0 | 3 | 1 | 3 | 1 | 0 | 0 | 1 | 1 |
2 to <6 Years | 8 | 3 | 2 | 1 | 1 | 0 | 2 | 0 | 1 | 0 | 0 |
6 to <13 Years | 12 | 6 | 5 | 1 | 2 | 0 | 0 | 2 | 1 | 0 | 0 |
7 reviews available for brl 42810 and Chickenpox
Article | Year |
---|---|
Antiviral agents: Non-antiretroviral [correction of Nonantiviral] drugs.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Cytomegalovirus Infections; Famciclovir; Fos | 2002 |
HIV: prevention of opportunistic infections.
Topics: 2-Aminopurine; Acyclovir; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-HIV Age | 2005 |
Successors to acyclovir.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Arabinofuranosyluracil; Chickenpox; Drug Resistance, Mic | 1994 |
Management of herpes simplex and varicella-zoster virus infections.
Topics: 2-Aminopurine; Acyclovir; Adult; Antiviral Agents; Chickenpox; Child; Famciclovir; Female; Herpes Si | 1997 |
Antiviral therapy of herpes simplex and varicella-zoster virus infections.
Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Antiviral Agents; Arabinofuranosyluracil; Bromodeoxy | 1997 |
Approaches to the treatment of varicella-zoster virus infections.
Topics: 2-Aminopurine; Acyclovir; Adrenal Cortex Hormones; Antiviral Agents; Chickenpox; Famciclovir; Guanin | 1999 |
[Varicella and zona: epidemiology, physiopathology, diagnosis, course, treatment].
Topics: 2-Aminopurine; Acyclovir; Adult; Aged; Antiviral Agents; Chickenpox; Child; Child, Preschool; Diagno | 1999 |
3 trials available for brl 42810 and Chickenpox
Article | Year |
---|---|
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Child; Child, Preschool; Drug Administration | 2009 |
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Child; Child, Preschool; Drug Administration | 2009 |
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Child; Child, Preschool; Drug Administration | 2009 |
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Child; Child, Preschool; Drug Administration | 2009 |
Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome.
Topics: 2-Aminopurine; Acyclovir; Adolescent; Adult; Antiviral Agents; Bone Marrow Transplantation; Chickenp | 2000 |
Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir.
Topics: 2-Aminopurine; Acyclovir; Adolescent; Adult; Age of Onset; Aged; Analysis of Variance; Antiviral Age | 2000 |